Given the promising early-stage results for Roche's oral obesity drug CT-996 and the anticipated disruption in the weight loss market, I believe investing in RHHBY offers substantial growth potential as it challenges dominant players like Eli Lilly and Novo Nordisk.

Roche is making strategic moves in developing GLP-1 drugs for weight loss and advancements in cancer immunotherapy, which could significantly drive its stock up in the short term. Their acquisition of Carmot Therapeutics further strengthens their position, making it a promising buy opportunity.

Roche is poised for short-term upside due to breakthroughs in cancer immunotherapy and entry into the lucrative weight-loss drug market with CT-996. The acquisition of Carmot Therapeutics and positive phase 1 results further support the potential for strong performance.